Breaking News Instant updates and real-time market news.

AMGN

Amgen

$187.16

-2.94 (-1.55%)

05:19
12/19/18
12/19
05:19
12/19/18
05:19

Amgen enters strategic collaboration with Molecular Partners

Amgen and Molecular Partners AG announced a collaboration and license agreement for the clinical development and commercialization of MP0310. MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells and co-stimulating T cells via 4-1BB. Under the terms of the agreement, Amgen obtains exclusive global development and commercial rights for MP0310. The parties will jointly evaluate MP0310 in combination with Amgen's oncology pipeline products, including its investigational BiTE molecules. Under the collaboration, Molecular Partners retains certain rights to develop and commercialize its proprietary DARPin pipeline products in combination with MP0310. Molecular Partners will receive an upfront payment of $50 million and is eligible to receive up to $497 million in development, regulatory and commercial milestone payments, as well as double-digit, tiered royalties up to the high teens. The parties will share the clinical development costs in defined percentages for the first three indications subject to certain conditions. For all additional clinical trials, Amgen is responsible for all development costs.

  • 16

    Jan

AMGN Amgen
$187.16

-2.94 (-1.55%)

12/18/18
HCWC
12/18/18
DOWNGRADE
HCWC
Neutral
Advaxis downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth downgraded Advaxis (ADXS) to Neutral without a price target. Amgen's (AMGN) termination of a development and collaboration agreement puts ADXS-NEO in limbo, Ramakanth tells investors in a research note. The analyst believes Amgen's withdrawal has "considerably increased" the development risk on ADXS-NEO and potentially ADXS-HOT as well. He steps to the sidelines "until the viability of the programs can be assured."
11/19/18
CANT
11/19/18
NO CHANGE
Target $68
CANT
Overweight
Tesaro could be worth $89-$97 per share in buyout, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young believes Tesaro (TSRO) could be valued at $89-$97 per share in a takeout scenario. The stock closed Friday up 31%, or $8.37, to $34.96 after Bloomberg reported that the company was exploring a sale after receiving some interest. The press article could be a way of garnering interest for the company beyond potentially initial interest, Young tells investors in a research note. In the past, she thinks Tesaro has been a potential takeout interest from biopharmaceutical companies. Companies like Amgen (AMGN), Gilead (GILD), and Celgene (CELG) have cancer platforms that could add a PARP inhibitor and benefit from Tesaro's various immuno-oncology pipeline assets, Young writes. She reiterates an Overweight rating on Tesaro with a $68 price target.
10/31/18
RBCM
10/31/18
NO CHANGE
Target $182
RBCM
Sector Perform
Amgen price target lowered to $182 from $193 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Amgen to $182 and kept his Sector Perform rating after its Q3 results. The analyst says the quarter was "in line" with "safe" expectations, even as the company's core business competition is "slow" to impact sales. MacKay further cites an "astonishing" launch of Aimovig with 100K new patients, but also notes the sales decline against sequential volume growth for Amgen's Repatha.
10/29/18
PIPR
10/29/18
NO CHANGE
PIPR
Neutral
Piper sees Amgen's Aimovig pressuring Allergan's Botox in near term
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Amgen (AMGN) and Neutral rating on Allergan (AGN) after his firm's Overweight based on feedback from a migraine survey fielded by his firm's partner Spherix Global Insights. The analyst is "struck by the progress" Amgen has made just months into Aimovig's launch, specifically on sales coverage, message delivery and overall credibility with physicians. It appears that Allergan's Botox "could be in for some pressure in the near term at the direct hands" of Amgen's Aimovig, Raymond tells investors in a research note titled "Aiming for Aimovig; New Migraine Survey Indicates Aimovig the Star of the Show." Doctors are projecting peak Aimovig share of 49% and 29% for chronic and episodic patients respectively, which infers peak U.S. revenue for the drug at $3.3B, the analyst says. Further, he notes that of the 98 high volume migraine specialists surveyed, 43% versus 29% agreed with the statement: "I am more likely to prescribe Aimovig over Botox due to access to patient assistance program."

TODAY'S FREE FLY STORIES

TROV

Trovagene

$1.03

-0.04 (-3.74%)

08:17
10/22/19
10/22
08:17
10/22/19
08:17
Hot Stocks
Trovagene announces data from Phase 1b/2 trial of onvansertib »

Trovagene announced data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARWR

Arrowhead

$36.48

0.5 (1.39%)

08:16
10/22/19
10/22
08:16
10/22/19
08:16
Recommendations
Arrowhead analyst commentary  »

Arrowhead price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRCB

Two River Bancorp

$21.00

0.15 (0.72%)

, OCFC

OceanFirst Financial

$23.96

0.18 (0.76%)

08:16
10/22/19
10/22
08:16
10/22/19
08:16
Earnings
Two River Bancorp reports Q3 EPS ex-items 35c, two est. 33c »

Net income was $2.1M, or…

TRCB

Two River Bancorp

$21.00

0.15 (0.72%)

OCFC

OceanFirst Financial

$23.96

0.18 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 29

    Oct

  • 13

    Nov

SGEN

Seattle Genetics

$100.86

13.44 (15.37%)

08:15
10/22/19
10/22
08:15
10/22/19
08:15
Recommendations
Seattle Genetics analyst commentary  »

Seattle Genetics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 07

    Dec

CTSO

CytoSorbents

$4.66

0.13 (2.87%)

08:15
10/22/19
10/22
08:15
10/22/19
08:15
Hot Stocks
CytoSorbents awarded $3M contract by U.S. Air force Materiel Command »

CytoSorbents announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:15
10/22/19
10/22
08:15
10/22/19
08:15
Conference/Events
Senate Commerce, Science & Transportation Committee to hold a hearing »

The Subcommittee on…

08:13
10/22/19
10/22
08:13
10/22/19
08:13
Conference/Events
Federal Reserve Bank of Dallas moderates a discussion »

Dallas Federal Reserve…

VRSK

Verisk Analytics

$153.42

-1 (-0.65%)

08:13
10/22/19
10/22
08:13
10/22/19
08:13
Hot Stocks
Property Damage Appraisers adopts Xactware's Xactimate solution »

Property Damage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

08:12
10/22/19
10/22
08:12
10/22/19
08:12
Conference/Events
Senate Banking, Housing & Urban Affairs Committee to hold a hearing »

The Committee holds a…

YETI

Yeti

$31.90

-0.54 (-1.66%)

08:12
10/22/19
10/22
08:12
10/22/19
08:12
Recommendations
Yeti analyst commentary  »

William Blair expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

PRO

Pros Holdings

$56.44

-0.46 (-0.81%)

, IBM

IBM

$132.55

-1.55 (-1.16%)

08:12
10/22/19
10/22
08:12
10/22/19
08:12
Hot Stocks
Pros Holdings announces John Allessio as chief customer officer »

Pros Holdings (PRO)…

PRO

Pros Holdings

$56.44

-0.46 (-0.81%)

IBM

IBM

$132.55

-1.55 (-1.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 27

    Oct

  • 18

    Nov

  • 19

    Nov

IR

Ingersoll-Rand

$117.95

0.65 (0.55%)

08:11
10/22/19
10/22
08:11
10/22/19
08:11
Conference/Events
Senate Energy & Natural Resources Committee to hold a hearing »

The Committee holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

BIIB

Biogen

$223.57

3.52 (1.60%)

08:11
10/22/19
10/22
08:11
10/22/19
08:11
Hot Stocks
Biogen CEO says aducanumab result gives hope for BAN2401 »

Michel Vounatsos,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

NTWK

NetSol Technologies

$5.27

-0.02 (-0.38%)

08:10
10/22/19
10/22
08:10
10/22/19
08:10
Hot Stocks
NetSol's NFS Ascent Wholesale Platform goes live in China for auto captive »

NETSOL Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:10
10/22/19
10/22
08:10
10/22/19
08:10
Conference/Events
The FDIC to hold a committee meeting »

The FDIC Advisory…

08:08
10/22/19
10/22
08:08
10/22/19
08:08
Conference/Events
CFTC Commissioner participates in a conference »

Dawn Stump, Commissioner…

VSAT

ViaSat

$71.91

0.43 (0.60%)

08:08
10/22/19
10/22
08:08
10/22/19
08:08
Hot Stocks
ViaSat announces business aviation connectivity approved by FAA »

Viasat announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCAR

Paccar

$72.88

0.83 (1.15%)

08:08
10/22/19
10/22
08:08
10/22/19
08:08
Earnings
Paccar reports Q3 EPS $1.75, consensus $1.65 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

KLDO

Kaleido Biosciences

$5.45

0.51 (10.33%)

08:07
10/22/19
10/22
08:07
10/22/19
08:07
Hot Stocks
Kaleido, Washington University School of Medicine announce collaboration »

Kaleido Biosciences has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMCR

Amcor

$9.68

0.09 (0.94%)

08:07
10/22/19
10/22
08:07
10/22/19
08:07
Initiation
Amcor initiated  »

Amcor initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AB

AllianceBernstein

$28.47

0.4 (1.43%)

, AVLR

Avalara

$66.83

0.435 (0.66%)

08:07
10/22/19
10/22
08:07
10/22/19
08:07
Conference/Events
Associated for Financial Professionals to hold a conference »

AFP 2019 will be held in…

AB

AllianceBernstein

$28.47

0.4 (1.43%)

AVLR

Avalara

$66.83

0.435 (0.66%)

AXP

American Express

$119.10

2.28 (1.95%)

BCS

Barclays

$8.52

0.04 (0.47%)

BBT

BB&T

$53.45

0.77 (1.46%)

BBD

Banco Bradesco

$8.15

-0.015 (-0.18%)

BK

BNY Mellon

$45.67

0.33 (0.73%)

BL

BlackLine

$47.58

1.19 (2.57%)

BLK

BlackRock

$453.79

8.53 (1.92%)

BMO

Bank of Montreal

$74.46

0.68 (0.92%)

C

Citi

$71.84

2.08 (2.98%)

COF

Capital One

$91.36

1.545 (1.72%)

DB

Deutsche Bank

$8.09

0.155 (1.95%)

FII

Federated Investors

$32.04

0.66 (2.10%)

FITB

Fifth Third

$28.04

0.71 (2.60%)

GS

Goldman Sachs

$209.30

2.69 (1.30%)

HSBC

HSBC

$39.14

0.42 (1.08%)

INTL

INTL FCStone

$40.36

0.36 (0.90%)

JPM

JPMorgan

$123.56

2.96 (2.45%)

MS

Morgan Stanley

$45.00

1.3 (2.97%)

MSFT

Microsoft

$138.43

1.09 (0.79%)

MTB

M&T Bank

$154.07

1.98 (1.30%)

MUFG

Mitsubishi UFJ

$5.14

0.105 (2.09%)

USB

U.S. Bancorp

$56.19

1.125 (2.04%)

V

Visa

$176.52

0.69 (0.39%)

WFC

Wells Fargo

$50.45

0.47 (0.94%)

WK

Workiva

$40.51

0.41 (1.02%)

SAP

SAP

$132.69

3.56 (2.76%)

STT

State Street

$65.42

2.02 (3.19%)

STI

SunTrust

$68.78

0.91 (1.34%)

TD

Toronto-Dominion

$56.80

0.34 (0.60%)

PRU

Prudential

$90.85

1.11 (1.24%)

UBS

UBS

$11.53

0.18 (1.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 26

    Oct

  • 27

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

  • 04

    Nov

  • 04

    Nov

  • 05

    Nov

  • 05

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 08

    Nov

  • 10

    Nov

  • 12

    Nov

  • 13

    Nov

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

  • 06

    Dec

  • 09

    Dec

  • 10

    Dec

  • 14

    Jan

  • 14

    Jan

  • 14

    Jan

  • 15

    Jan

AIR

AAR Corp.

$40.18

0.37 (0.93%)

08:06
10/22/19
10/22
08:06
10/22/19
08:06
Hot Stocks
AAR subsidiary signs agreement with JetBlue »

AAR subsidiary Airinmar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZRX

AzurRx BioPharma

$0.81

0.04 (5.19%)

08:06
10/22/19
10/22
08:06
10/22/19
08:06
Hot Stocks
AzurRx BioPharma CEO says 'on track' to meet with FDA in December »

AzurRx BioPharma issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$209.85

1.365 (0.65%)

08:05
10/22/19
10/22
08:05
10/22/19
08:05
Hot Stocks
McDonald's CEO says 'our third quarter performance was strong' »

"Our third quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

NVIV

InVivo Therapeutics

$0.49

0.03 (6.52%)

08:04
10/22/19
10/22
08:04
10/22/19
08:04
Hot Stocks
InVivo Therapeutics announces INSPIRE 2.0 study at 25% enrollment »

InVivo Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.